Platinum agent combination treatment for triple-negative breast cancer well tolerated in phase II clinical trial

New research shows that a combination of doxil, carboplatin and bevacizumab is a well-tolerated treatment regimen in patients with metastatic triple-negative breast cancer who received no prior treatment for their metastatic disease. The work also included genomic profiling to measure molecular correlates of response.

Read the whole article on Science Daily

More from Science Daily